The Journal of Thoracic and Cardiovascular Surgery
Volume 127, Issue 2 , Pages 376-384, February 2004

Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

  • Steven M. Woolley, MRCS

      Affiliations

    • Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash, USA
  • ,
  • Alexander S. Farivar, MD

      Affiliations

    • Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash, USA
  • ,
  • Babu V. Naidu, FRCS

      Affiliations

    • Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash, USA
  • ,
  • Matthew Rosengart, MD

      Affiliations

    • Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash, USA
  • ,
  • Robert Thomas, BA

      Affiliations

    • Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash, USA
  • ,
  • Charles Fraga, MS

      Affiliations

    • Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash, USA
  • ,
  • Michael S. Mulligan, MD, FACS

      Affiliations

    • Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash, USA
    • Corresponding Author InformationAddress for reprints: Michael Mulligan, MD, FACS, Box 356310, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA

Received 2 May 2003; received in revised form 25 September 2003; accepted 30 September 2003.

Abstract 

Objectives

We previously demonstrated that calcineurin inhibitors given intravenously ameliorate experimental lung ischemia-reperfusion injury. This study evaluates whether these effects can be achieved when these agents are delivered endotracheally.

Methods

Left lungs of Long Evans rats were rendered ischemic for 90 minutes and reperfused for up to 4 hours. Treated animals received tacrolimus endotracheally at doses of 0.2, 0.1, or 0.025 mg/kg 60 minutes before ischemia. Injury was quantitated in terms of vascular permeability. Additional animals treated at a dose of 0.1 mg/kg were assessed for lung tissue myeloperoxidase content and bronchoalveolar lavage leukocyte content. Bronchoalveolar lavage fluid was assessed for cytokine and chemokine content by enzyme-linked immunosorbent assay. Tissue samples were processed for nuclear factor-κB activation, and blood levels of tacrolimus were measured in treated animals.

Results

Left lung vascular permeability was reduced in treated animals in a dose-dependent fashion compared with controls. The protective effects correlated with a 47% (0.50% ± 0.06% vs 0.27% ± 0.08%, respectively) reduction in tissue myeloperoxidase content (P < .004) and marked reductions in bronchoalveolar lavage leukocyte accumulation. This protection was also associated with decreased nuclear factor-κB activation and diminished expression of proinflammatory mediators. Blood tacrolimus levels in treated animals at 4 hours of reperfusion were undetectable.

Conclusions

Tacrolimus administered endotracheally is protective against lung ischemia-reperfusion injury in our model. This protection is associated with a decrease in nuclear factor-κB activation. This route of tacrolimus administration broadens its potential clinical use and decreases concerns about systemic and renal toxicity. It may be a useful therapy in lung donors to protect against lung ischemia-reperfusion injury.

Keywords: 12

 

PII: S0022-5223(03)01794-X

doi:10.1016/j.jtcvs.2003.09.034

The Journal of Thoracic and Cardiovascular Surgery
Volume 127, Issue 2 , Pages 376-384, February 2004